Advertisement

Hormones

, Volume 16, Issue 4, pp 362–372 | Cite as

Detection rate of somatostatin receptor PET in patients with recurrent medullary thyroid carcinoma: a systematic review and a meta-analysis

  • Giorgio Treglia
  • Adriana Tamburello
  • Luca Giovanella
Review
  • 16 Downloads

Abstract

PURPOSE: Several articles have demonstrated the high diagnostic performance of somatostatin receptor positron emission tomography (PET) in patients with neuroendocrine tumours (NETs). on the other hand, only a few studies have evaluated the detection rate (DR) of this imaging method in recurrent medullary thyroid carcinoma (MTC). We aimed to perform a systematic review and a meta-analysis of the DR of somatostatin receptor PET or PET/CT in patients with recurrent MTC to add evidence-based data to this setting. METHODS: A comprehensive computer literature search of studies published in PubMed/MEDLINE and the Cochrane Library Database through may 2017 and regarding somatostatin receptor PET or PET/CT in patients with recurrent MTC was carried out. DR was determined on a per patient-basis. A sub-analysis considering serum calcitonin (Ctn) values was also performed. RESULTS: Nine studies on the diagnostic performance of somatostatin receptor PET or PET/CT in detecting recurrent MTC were discussed in the systematic review. The meta-analysis of these selected studies provided the following DR on a per patient-based analysis: 63.5% [95% confidence interval (95%CI): 49–77]. Heterogeneity among the selected studies was found. DR of somatostatin receptor PET or PET/CT increased in patients with higher serum Ctn levels (83% for Ctn >500 ng/L). CONCLUSIONS: In patients with recurrent MTC, somatostatin receptor PET or PET/CT demonstrated a non-optimal DR which increased in patients with higher serum Ctn values. The diagnostic performance of somatostatin receptor PET or PET/CT in recurrent MTC is lower compared to that of the same imaging method in the majority of NETs.

Key words

Gallium Medullary thyroid carcinoma Positron emission tomography PET/CT Somatostatin Thyroid cancer 

References

  1. 1.
    Wells SA Jr, Asa SL, Dralle H, et al, 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25: 567–610.CrossRefGoogle Scholar
  2. 2.
    Rufini V, Castaldi P, Treglia G, et al, 2008 Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma. Biomed Pharmacother 62: 139–146.CrossRefGoogle Scholar
  3. 3.
    Rufini V, Treglia G, Perotti G, Leccisotti L, Calcagni ML, Rubello D, 2008 Role of PET in medullary thyroid carcinoma. Minerva Endocrinol 33: 67–73.PubMedGoogle Scholar
  4. 4.
    Trimboli P, Crescenzi A, Saggiorato E, Treglia G, Giovanella L, 2017 Novel acquisitions in the diagnosis of medullary thyroid carcinoma. Minerva Endocrinol 42: 238–247.PubMedGoogle Scholar
  5. 5.
    Treglia G, Rufini V, Salvatori M, Giordano A, Giovanella L, 2012 PET imaging in recurrent medullary thyroid carcinoma. Int J Mol Imaging 2012: 324686.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Treglia G, Giovanella L, Rufini V, 2013 PET and PET/CT imaging in thyroid and adrenal diseases: an update. Hormones 12: 327–333.CrossRefGoogle Scholar
  7. 7.
    Treglia G, Muoio B, Giovanella L, Salvatori M, 2013 The role of positron emission tomography and positron emission tomography/computed tomography in thyroid tumours: an overview. Eur Arch Otorhinolaryngol 270: 1783–1787.CrossRefGoogle Scholar
  8. 8.
    Treglia G, Sadeghi R, Del Sole A, Giovanella L, 2014 Diagnostic performance of PET/CT with tracers other than F-18-FDG in oncology: an evidence-based review. Clin Transl Oncol 16: 770–775.CrossRefGoogle Scholar
  9. 9.
    Barrio M, Czernin J, Fanti S, et al, 2017 The impact of somatostatin receptor-directed PET/CT on the management of patients with neuroendocrine tumor: A systematic review and meta-analysis. J Nucl Med 58: 756–761.CrossRefGoogle Scholar
  10. 10.
    Deppen SA, Blume J, Bobbey AJ, et al, 2016 68GaDOTATATE compared with 111In-DTPA-Octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: A systematic review and meta-analysis. J Nucl Med 57: 872–878.CrossRefGoogle Scholar
  11. 11.
    Yang J, Kan Y, Ge BH, Yuan L, Li C, Zhao W, 2014 Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis. Acta Radiol 55: 389–398.CrossRefGoogle Scholar
  12. 12.
    Geijer H, Breimer LH, 2013 Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 40: 1770–1780.CrossRefGoogle Scholar
  13. 13.
    Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V, 2012 Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine 42: 80–87.CrossRefGoogle Scholar
  14. 14.
    Treglia G, Villani MF, Giordano A, Rufini V, 2012 Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis. Endocrine 42: 535–545.CrossRefGoogle Scholar
  15. 15.
    Cheng X, Bao L, Xu Z, et al, 2012 18F-FDG-PET and 18F-FDG-PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: a systematic review and meta-analysis. J Med Imaging Radiat Oncol 56: 136–142.CrossRefGoogle Scholar
  16. 16.
    Treglia G, Cocciolillo F, Di Nardo F, et al, 2012 Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 dihydroxyphenylalanine positron emission tomography: a meta-analysis. Acad Radiol 19: 1290–1299.CrossRefGoogle Scholar
  17. 17.
    Rufini V, Treglia G, Montravers F, Giordano A, 2013 Diagnostic accuracy of [18F]DOPA PET and PET/CT in patients with neuroendocrine tumors: a meta-analysis. Clin Transl Imaging 1: 111–122.CrossRefGoogle Scholar
  18. 18.
    Moher D, Liberati A, Tetzlaff J, Altman DG, 2009 Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62: 1006–1012.CrossRefGoogle Scholar
  19. 19.
    Sadeghi R, Treglia G, 2017 Systematic reviews and meta-analyses of diagnostic studies: a practical guideline. Clin Transl Imaging 5: 83–87.CrossRefGoogle Scholar
  20. 20.
    Oxford Center for Evidence-Based Medicine checklist for diagnostic studies appraisal. Available at: https://doi.org/www.cebm.net. Accessed June 1st 2017.
  21. 21.
    Yamaga LYI, Cunha ML, Campos Neto GC, et al, 2017 (68)Ga-DOTATATE PET/CT in recurrent medullary thyroid carcinoma: a lesion-by-lesion comparison with (111)In-octreotide SPECT/CT and conventional imaging. Eur J Nucl Med Mol Imaging 44:1695–1701.CrossRefGoogle Scholar
  22. 22.
    Tran K, Khan S, Taghizadehasl M, et al, 2015 Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin. Hell J Nucl Med 18: 19–24.PubMedGoogle Scholar
  23. 23.
    Ozkan ZG, Kuyumcu S, Uzum AK, et al, 2015 Comparison of 68Ga-DOTATATE PET-CT, 18F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma. Nucl Med Commun 36: 242–250.CrossRefGoogle Scholar
  24. 24.
    Traub-Weidinger T, Putzer D, von Guggenberg E, et al, 2015 Multiparametric PET imaging in thyroid malignancy characterizing tumour heterogeneity: somatostatin receptors and glucose metabolism. Eur J Nucl Med Mol Imaging 42: 1995–2001.CrossRefGoogle Scholar
  25. 25.
    Treglia G, Castaldi P, Villani MF, et al, 2012 Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 39: 569–580.CrossRefGoogle Scholar
  26. 26.
    Naswa N, Sharma P, Suman Kc S, et al, Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Nucl Med Commun 33: 766–774.Google Scholar
  27. 27.
    Lapinska G, Bryszewska M, Fijolek-Warszewska A, Kozlowicz-Gudzinska I, Ochman P, Sackiewicz-Slaby A, 2011 The diagnostic role of 68Ga-DOTATATE PET/CT in the detection of neuroendocrine tumours. Nucl Med Rev Cent East Eur 14: 16–20.CrossRefGoogle Scholar
  28. 28.
    Pałyga I, Kowalska A, Gąsior-Perczak D, et al, 2010 The role of PET-CT scan with somatostatin analogue labelled with gallium-68 (68Ga-DOTA-TATE PET-CT) in diagnosing patients with disseminated medullary thyroid carcinoma (MTC). Endokrynol Pol 61: 507–511.PubMedGoogle Scholar
  29. 29.
    Conry BG, Papathanasiou ND, Prakash V, et al, 2010 Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 37: 49–57.CrossRefGoogle Scholar
  30. 30.
    Herac M, Niederle B, Raderer M, et al, 2016 Expression of somatostatin receptor 2A in medullary thyroid carcinoma is associated with lymph node metastasis. APMIS 124: 839–845.CrossRefGoogle Scholar
  31. 31.
    Woelfl S, Bogner S, Huber H, et al, 2014 Expression of somatostatin receptor subtype 2 and subtype 5 in thyroid malignancies. Nuklearmedizin 53: 179–185.CrossRefGoogle Scholar
  32. 32.
    Papotti M, Kumar U, Volante M, et al, 2001 Immunohistochemical detection of somatostatin receptor types 1–5 in medullary carcinoma of the thyroid. Clin Endocrinol (Oxf) 54: 641–649.CrossRefGoogle Scholar
  33. 33.
    Zatelli MC, Tagliati F, Taylor JE, Rossi R, Culler MD, degli Uberti EC, 2001 Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line tt. J Clin Endocrinol Metab 86: 2161–2169.PubMedGoogle Scholar
  34. 34.
    Treglia G, Rindi G, Rufini V, 2012, Expression of somatostatin receptors may guide the use of somatostatin receptor imaging and therapy in differentiated thyroid cancer. Hormones 11: 230–232.CrossRefGoogle Scholar
  35. 35.
    Treglia G, Aktolun C, Chiti A, et al, 2016 The 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the “evidence-based” refusal to endorse them by EANM due to the “not evidence-based” marginalization of the role of Nuclear Medicine. Eur J Nucl Med Mol Imaging 43: 1486–1490.CrossRefGoogle Scholar
  36. 36.
    Maffione AM, Giammarile F, Rubello D, 2017 SPECT/CT and PET/CT molecular imaging in medullary thyroid carcinoma. Are we running in the right direction? Eur J Nucl Med Mol Imaging 44: 1692–1694.CrossRefGoogle Scholar
  37. 37.
    Treglia G, Castaldi P, Villani MF, et al, 2013 Comparison of different positron emission tomography tracers in patients with recurrent medullary thyroid carcinoma: our experience and a review of the literature. Recent Results Cancer Res 194: 385–393.CrossRefGoogle Scholar
  38. 38.
    Slavikova K, Montravers F, Treglia G, et al, 2013 What is currently the best radiopharmaceutical for the hybrid PET/CT detection of recurrent medullary thyroid carcinoma? Curr Radiopharm 6: 96–105.CrossRefGoogle Scholar
  39. 39.
    Treglia G, Stefanelli A, Castaldi P, et al, 2013 A standardized dual-phase 18F-DOPA PET/CT protocol in the detection of medullary thyroid cancer. Nucl Med Commun 34: 185–186.CrossRefGoogle Scholar
  40. 40.
    Soussan M, Nataf V, Kerrou K, et al, 2012 Added value of early 18F-FDOPA PET/CT acquisition time in medullary thyroid cancer. Nucl Med Commun 33: 775–779.CrossRefGoogle Scholar
  41. 41.
    Bozkurt MF, Virgolini I, Balogova S, et al, 2017 Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. Eur J Nucl Med Mol Imaging 44: 1588–1601.CrossRefGoogle Scholar
  42. 42.
    Salavati A, Puranik A, Kulkarni HR, Budiawan H, Baum RP, 2016 Peptide Receptor Radionuclide Therapy (PRRT) of Medullary and Nonmedullary Thyroid Cancer Using Radiolabeled Somatostatin Analogues. Semin Nucl Med 46: 215–224.CrossRefGoogle Scholar

Copyright information

© Hellenic Endocrine Society 2017

Authors and Affiliations

  • Giorgio Treglia
    • 1
    • 2
    • 3
  • Adriana Tamburello
    • 1
  • Luca Giovanella
    • 1
  1. 1.Nuclear Medicine and PET/CT CenterOncology Institute of Southern SwitzerlandBellinzonaSwitzerland
  2. 2.Health Technology Assessment UnitGeneral Directorate, Ente Ospedaliero CantonaleBellinzonaSwitzerland
  3. 3.Nuclear Medicine and Molecular ImagingCHUV University HospitalLausanneSwitzerland

Personalised recommendations